Introduction
In the past, genome-wide association (GWA) studies have been successful in elucidating the genetic background of complex diseases. In these studies, single nucleotide polymorphisms (SNPs) are tested for association with a disease or phenotype. The focus of GWA studies and subsequent meta-analyses, however, has been on the autosomes, whereas X chromosomal data have usually been collected but not analyzed [1] [2] [3] [4] .
The probable reason for this neglect is that handling of X chromosomal genotype data is not yet standardized: there are no standard statistics established to test for association, and although special criteria for quality control have been defined, no standard thresholds for these have been approved [5] . Also, different genotype-calling algorithms are needed for the X chromosome which are not implemented in all programs. As a consequence, only few associations have been reported for the X chromosome, in contrast to numerous established associations on the autosomes [6] . Thus, the genetic information located on the X chromosome is to a great extent lost. This is even more dramatic since the inheritance patterns of many complex diseases are known to be sex-determined, which should ascribe vital importance to the analysis of X chromosomal data.
To acknowledge the specific characteristics of X chromosomal data, we need to bear in mind that for the autosomes, males and females carry two copies of each chromosome, resulting in three possible genotypes per SNP. For females, this also holds for the X chromosome. Males, however, have one X chromosome and one Y chromosome. For some loci on the X chromosome, the so-called 'pseudo-autosomal' loci, homologous loci on the Y chromosome exist, so that both males and females, again, carry two alleles per SNP. For the remaining loci, males carry only one allele at each SNP, resulting in only two possible genotypes per SNP. While SNPs in pseudo-autosomal regions can be analyzed by known association tests for autosomes [7] , SNPs on other X chromosomal loci need special treatment as soon as the sample analyzed contains both male and female subjects.
A further special feature of the X chromosome is the process of inactivation. Early in embryonic development, great parts of one of the two female X chromosomes are silenced by the XIST RNA [8] . It has been suggested that this is a mechanism of dosage compensation, resulting in equal effects for one copy of the X chromosome in males and two copies in females. Considering disease predisposing loci, this means that males with one risk allele have a comparable risk to females homozygous for the risk allele. It is estimated that about three quarters of X chromosomal genes are silenced on one of the female X chromosomes, while the remaining loci may escape inactivation in some females [9] .
So far, there has been little work regarding association tests for markers on the X chromosome. Zheng et al. [10] proposed different tests for a model without taking the possible inactivation of the female X chromosome into account. They also provide results from a simulation study demonstrating power and error levels of the presented tests in some basic situations. A number of interesting situations that include differences between male and female sub-samples were not considered, such as different numbers of males and females in the sample and different proportions of males and females in cases and controls, or different effect sizes for males and females.
Another approach was taken by Clayton [11] , who derived tests modeling one of the female X chromosomes as inactivated. Clayton [11] does not present a simulation study concerning power and error levels of the suggested tests, but they were applied in a GWA setting [12] . A systematic comparison of all test statistics proposed by Zheng et al. [10] and Clayton [11] is still missing. The purpose of this article is therefore to compare these tests with regard to power and error levels in a wide range of settings. In order to do so, we simulated SNP association data for a sample of males and females. We considered models with and without inactivation of one female X chromosome. Besides characteristics of the general population, we investigated a variety of sex-specific parameters, including differences in effect sizes, allele frequencies and prevalence between males and females. Furthermore, we considered unbalanced sampling procedures resulting in different numbers of females and males in the sample or in a sex-specific composition of case and control samples. Additionally, we applied the test statistics to the analysis of a sample of 300 Crohn's disease cases and 432 unrelated controls.
Materials and Methods
Existing tests for associations on the X chromosome make different assumptions on the influence of a single allele in females compared to males. The intuitive approach is to simply count alleles in males and females, suggesting that one allele in a male subject has the same influence as one allele in a female subject. This corresponds to a model with both female X chromosomes active. Under this assumption, males with one risk allele are treated like heterozygous females. Another strategy takes the idea of X chromosome inactivation into account. Here, males are treated like homozygous females. Zheng et al. [10] proposed different tests for a model without X inactivation, whereas Clayton [11] derived tests modeling one of the female X chromosomes as inactivated.
Allele and genotype counts for SNPs on the X chromosome are presented in table 1 (adapted from Zheng et al. [10] ), and details of all test statistics are summarized in table 2 .
Test Statistics Assuming No X Inactivation
The first test proposed by Zheng et al. [10] is the allele-based test for the entire sample of males and females, Z 2 A . Here, differences in allele counts between cases and controls are compared jointly for males and females ( table 1 d). This is the most intuitive approach, but under departure from Hardy-Weinberg equilibrium (HWE), allele-based test statistics like Z 2 A are known to deviate from the proposed distribution, which reduces the reliability of the test results [13] . Additionally, allele frequencies are estimated over the entire sample, which, again, may lead to a violation of distribution assumptions for sex-specific allele frequencies.
The [7] .
Zheng et al. [10] also proposed two tests for situations where the effect alleles for males and females are different. These are not considered here, since we do not regard this as biologically plausible.
Test Statistics Assuming X Inactivation
We first consider two score test statistics proposed by Clayton [11] , one testing for an additive genetic model and the other testing for both additive and dominant models of inheritance. Both tests are derived for a general phenotype and a biallelic locus.
Clayton's [11] additive test, T A , corresponds to the usual Cochran-Armitage trend test for a completely female sample and differs from this as soon as the sample contains males. The genotype counts in females, A i , take values 0, 1 or 2 corresponding to 0, 1 or 2 risk alleles, respectively. For males, values 0 or 2 are possible corresponding to 0 or 1 risk allele. This genotype coding is based on X chromosomal inactivation and the assumption that two risk alleles in females have the same effect as one risk allele in males. The score of the additive model, U A , is calculated over the entire sample. This is based on the assumption of equal allele frequencies for males and females. If these differ, the distribution assumptions for T A do not hold. Since variances in female and male samples differ, these must be calculated separately for the two subgroups even for equal allele frequencies in males and females.
To model a dominant effect, Clayton [11] introduces a heterozygosity indicator, D , taking the value 1 for heterozygotes and 0 for homozygotes. As there are no heterozygous males, D is set to 0 for all men. Combining the additive score U A and the dominant score U D , Clayton [11] derives a 2-d.f. score test, which should be able to detect both additive and dominant genetic effects. Again, the covariances of U A and U D have to be calculated separately for male and female subsamples. The test T AD also requires equal allele frequencies in males and females. But since both T A and T AD are based on genotype counts rather than allele counts, they remain valid under departure from HWE in females.
If allele frequencies differ between sexes, stratified tests need to be calculated. Clayton [11] proposed to calculate the abovementioned test T AD in exactly the same way separately for males and females and to then add both test statistics. Since for males no dominance term is calculated, this test has 3 d.f. Equivalently, a stratified version of the test T A can be calculated. This would lead to a 2-d.f. test statistic, T s A , asymptotically equivalent to the test Z 2 C proposed by Zheng et al. [10] , and will therefore not be considered. Another possibility to calculate a stratified test for the additive model is to weigh the (additive) scores for males and females with their inverse variances. This yields the test S A proposed by Ziegler and König [7] , which is 2 distributed with 1 d.f.
Simulation Study
We simulated a sample of 400 subjects. Estimates for type I error frequencies and power of the different test statistics are based on 10,000 replications for every scenario, which results in a precision of at least 0.99 at a confidence of at least 0.95 for any proportion. The alternative hypothesis of association between phenotype and genotype was specified by the genotypic relative risks. Let a and A be the risk and the other allele, respectively. Casecontrol genotype data for females were generated according to Wittke-Thompson et al. (their Appendix A and B) [14] by using the heterozygous relative risk Cases
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Sample Designs
We considered balanced and unbalanced sample designs. For the balanced design, we generated a sample of 100 female cases, 100 female controls, 100 male cases and 100 male controls. For the unbalanced design, we first simulated a sample of 150 females and 250 males and a sample of 250 females and 150 males, keeping the distribution of females and males to cases and controls balanced. Second, we simulated samples of 200 females and 200 males, now changing the ratios of males and females in cases and controls. Specifically, we simulated one sample with 67% females in cases and 33% females in controls and a second sample with 33% females in cases and 67% females in controls.
Departure from HWE
To examine the influence of departure from HWE, we simulated a balanced sample design where males and females do not differ in any parameter. For X chromosomal SNPs, HWE can be violated in the female sample only. When HWE holds, genotype frequencies of females are given by
f , where p f is the risk allele frequency for females. We now measured departure from HWE by the difference
The extent of departure from HWE is here modeled by the proportion of excess or deficiency of heterozygosity, ⌬ = * p f (1 -p f ), where a positive value of indicates a deficiency of heterozygotes and a negative one an excess of heterozygotes.
Sex-Specific Allele Frequencies
Allele frequency differences between males and females were considered in balanced as well as unbalanced sample designs because unbalanced sample designs can have an additional influence on power and type I error frequencies.
Simulation of Type I Error
To assess the validity of the test statistics, we investigated type I error frequencies under the null hypothesis of no association. Specifically, we simulated departures from HWE with values for between -0.4 and 0.4 and differences in allele frequencies between males and females of 0.02-0.1.
Simulation of Power
To determine the power of the different tests, we simulated case-control data under each genetic model listed in table 3 . Relative risks were varied between 1.0 and 3.0. We simulated data in HWE and under departure from HWE in females ( = 8 0.2). Besides characteristics of the general population, we investigated a variety of sex-specific parameters. We simulated differences in effect sizes by reducing the homozygous relative risk ␥ 2 in females or the relative risk ␥ in males by 50%. To consider differences in prevalence between males and females, we simulated a prevalence of 0.05 in males and 0.15 in females and vice versa. These parameters were simulated under a balanced sample design and changed separately, keeping all other parameters identical for both sexes. Additionally, we simulated differences in allele frequencies between males and females of 0.05 and 0.1 for balanced and unbalanced sample designs.
Data -Crohn's Disease
We applied the test statistics to real data from a Crohn's disease GWA study previously described by Duerr et al. [15] and Rioux et al. [16] . The study was funded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) IBD Genetics Consortium (IBDGC). The data set contained genetic information of a sample of 300 Crohn's disease cases with ileal involvement and 432 unrelated controls matched to cases based on sex and year of birth. Both groups had Jewish ancestry. The entire sample consists of 336 females and 396 males. Individuals with a call rate ! 90% or genotypes incompatible with the recorded sex were excluded from analysis. Genotyping was done using the Illumina HumanHap300 Genotyping BeadChip, which contains 8,706 X chromosomal SNPs outside of the pseudo-autosomal regions. Male heterozygous calls were SNP-wise excluded. Likewise, SNPs with 6 2% heterozygous calls were excluded from analysis. According to the Travemunde criteria [1, 2, 5] , we excluded SNPs with a MAF ! 0.01, SNPs with a genotypic call fraction ! 0.98 in either cases or controls, and SNPs with p ! 10 -4 in the test for departure from HWE in the female control sample. 
Model without X inactivation Recessive
␥ 1 = Heterozygous relative risk for females; ␥ 2 = homozygous relative risk for females; ␥ = relative risk for males. 
Results

Type I Error -Departure from HWE
Type I Error -Sex-Specific Allele Frequencies
Under a balanced sample design, differences in allele frequencies between sexes ( table 4 ) seem to be relevant primarily for the tests T A and T AD proposed by Clayton [11] . These show increased error frequencies when the allele frequencies of males are higher than those of females, and vice versa they show decreased error frequencies. This is especially pronounced with mean MAFs ^ 0.3 in the overall sample, where the proportional difference relative to the mean MAF is higher. mfA show a slight inflation of type I error for MAFs near 0.5 when numbers of males and females in the total sample differ (online suppl. table 2). Such differences show no additional effect on the error frequencies of T A and T AD as long as the ratios of males and females in cases and controls are equal, but error frequencies increase with different ratios (online suppl. table 3: unbalanced design of 67% female cases and 33% female controls; results for 33% female cases and 67% female controls are comparable and therefore omitted). Differences in allele frequencies for this sample design inflate error frequencies of the tests Z Figure 1 shows the empirical power at a MAF of 0.3 of the eight tests under the different genetic models summarized in table 3 . To facilitate better discrimination of test statistics in power curves, a colored line and a specific symbol is drawn for each test. Note that for a dominant model of inheritance, X chromosomal inactivation is not relevant since both inactivation and no inactivation lead to the same model. The presented results were simulated under the assumption of HWE. Under departure from HWE in females, the allele-based tests are not valid and were therefore not evaluated. Power of all other test statistics was not essentially affected by departures from HWE; therefore these results are not shown.
Power -Balanced Sample Designs
For a dominant model of inheritance, there are only small differences in power between the different tests. Under all but the recessive models, the 3-d.f. test T s AD has considerably less power than all other tests. In situations with X inactivation, the test T A proposed by Clayton [11] shows generally good power properties, closely followed by Z 2 2 mfG proposed by Zheng et al. [10] . Remarkably, the test T AD shows no obvious advantage compared to T A in the recessive and dominant models, although it has a special term measuring heterozygosity in females.
In models without X chromosomal inactivation power is generally lower. The reason for this is that under this assumption the effect of males is equal to the heterozygous relative risk instead of the homozygous relative risk so that, in the additive model, males show only half the effect compared to a model with inactivation, and in the recessive model, there is no effect in the male sample. Generally, the allele-based tests Z In general, different MAFs lead to comparable power results (additional figures are shown in online suppl. fig. 1-4) . However, differences between tests become more prominent with smaller MAFs in the recessive model with X chromosomal inactivation (online suppl. fig. 1, 2 ). Here, tests T A and T AD show considerable superiority, and test S A seems to have little power to detect an effect. In a recessive model without inactivation, there is almost no power to detect an effect for MAFs around 0.1 and lower (online suppl. fig. 1, 2) .
Power -Unbalanced Sample Designs
Different numbers of males and females in the sample have nearly no effect on power as long as the ratio of males to females is the same for cases and controls (online suppl. fig. 5, 6 ). If, however, there are different ratios of males to females in cases and controls, we do observe distinct differences in power. Results for the recessive model are shown in figure 2 . With 67% females in cases and 33% in controls, differences compared to the balanced design are small in the dominant model and both additive models but become more pronounced in the recessive models. In models without X inactivation and for MAFs ^ 0.1, in the dominant model, Z C performs best and retains about the same power as it has in the balanced design (online suppl. fig. 7-14) . With 33% female cases and 67% female controls, differences in power between tests become even more pronounced. Nevertheless, the tests with highest and lowest power in most cases remain the same as in the balanced sample design. But again, test Z 2 A now shows superiority in the recessive model without inactivation and, for MAFs ^ 0.1, in the dominant model.
Power -Sex-Specific Prevalences, Effect Sizes and Allele Frequencies
Differences in disease prevalence between sexes seem to have no influence on the power performance of the different test statistics (online suppl. fig. 15, 16) . Differences in effect size between males and females, though, seem to be crucial. We did not consider the recessive model without X inactivation in these settings since there is no effect in the male sample. Results for the additive models with and without inactivation for a MAF of 0.3 are shown in figure 3 .
As the effect is reduced in one of the two sexes, power is generally expected to be lower, which can clearly be observed for all genetic models ( fig. 3 , online suppl. fig. 17-24 ). When the effect in the male sample is reduced by 50%, the allele-based tests Z and test S A are superior again. When the effect is reduced in the female sample, on the other hand, T A has the highest power over all genetic models and all MAFs. Especially for the additive model with X inactivation, this difference becomes more distinct in this situation.
Under sex-specific allele frequencies, tests T A , T AD and, for sex-specific compositions of cases and controls, Z fig. 25-30) . Note that unbalanced sample designs show no additional effect on the power of test statistics valid under sex-specific allele frequencies.
Analysis of Crohn's Disease Data
After quality control, 294 cases and 431 controls were left for analysis genotyped at 7,546 X chromosomal SNPs. After a conservative Bonferroni correction for multiple testing, we fixed the chromosome-wide significance threshold at 5 ؒ 10 -6 . Although absolute numbers of males and females as well as absolute numbers of cases and controls differ, we have about the same proportion of females in cases (47%) and in controls (45%). For all SNPs reported below, MAFs were 1 0.2, and the difference in allele frequencies between males and females was ! 0.05. Therefore, we do not expect the tests Z fig. 32 ).
Looking at the genotype counts for the top SNP rs2038265, it may be suggested that the risk for Crohn's disease is increased especially for female homozygotes for the C allele and for males with a C allele, hinting at a recessive model of inheritance with X inactivation. For SNP rs7889974, the effect seems to be more pronounced in females since the p value in the male sample is considerably higher than in the female sample. In both cohorts, though, the risk of Crohn's disease seems to increase with the number of G alleles. For two further SNPs in this region (rs2207272, rs2144096) T AD yields the minimal p value. For SNPs rs7056485 and rs5908216, T A yields the minimal p value; here, the effect appears to result primarily from males since p values for females are 1 0.05. SNP rs4829424 near NR0B1 and MAGEB (online suppl. fig. 33 ) displays a purely female effect on the susceptibility for Crohn's disease ( Z fG results in p values 1 0.7. For these SNPs, the effect seems to arise from a heterozygosity deficit in female cases (online suppl. fG are 1 0.05). For these SNPs, the effect seems to arise from a heterozygosity excess in female cases (online suppl. table 5).
Discussion
Different tests for association on the X chromosome have been proposed in the literature [10, 11] , but there has so far been no systematic comparison between them. To close this gap, we conducted a broadly conceived simulation study comparing tests in a wide range of settings. Additionally, we applied the tests to the analysis of a real data set. The aim was to facilitate researchers' choice of an appropriate test for detecting associations for X chromosomal SNPs.
Results from simulations under the null hypothesis of no association reveal that the tests Z 2 A , T A , and T AD are not valid under sex-specific allele frequencies, especially when ratios of males to females differ between cases and controls. For these unbalanced sample designs, even minor differences in allele frequencies between sexes can lead to a crucial inflation of type I error frequencies; here, tests Z 2 A , T A , and T AD should not be used. It is therefore recommended to check for differences in allele frequencies between males and females before applying tests. As expected, departure from HWE is problematic for the allele-based tests Z mfA which should only be used after compatibility with HWE is established.
Results from power simulations as well as from the real data analysis demonstrate that no test is uniformly best over all genetic models. As could be expected, Clayton's [11] additive test T A is most powerful for most models assuming X inactivation. If the effect size in females is 
